PL2443104T3 - Dwupodstawione pochodne ftalazyny będące antagonistami ścieżki hedgehog - Google Patents
Dwupodstawione pochodne ftalazyny będące antagonistami ścieżki hedgehogInfo
- Publication number
- PL2443104T3 PL2443104T3 PL10726756T PL10726756T PL2443104T3 PL 2443104 T3 PL2443104 T3 PL 2443104T3 PL 10726756 T PL10726756 T PL 10726756T PL 10726756 T PL10726756 T PL 10726756T PL 2443104 T3 PL2443104 T3 PL 2443104T3
- Authority
- PL
- Poland
- Prior art keywords
- hedgehog pathway
- pathway antagonists
- disubstituted phthalazine
- phthalazine hedgehog
- disubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21862809P | 2009-06-19 | 2009-06-19 | |
| EP10726756.9A EP2443104B1 (en) | 2009-06-19 | 2010-06-15 | Disubstituted phthalazine hedgehog pathway antagonists |
| PCT/US2010/038568 WO2010147917A1 (en) | 2009-06-19 | 2010-06-15 | Disubstituted phthalazine hedgehog pathway antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2443104T3 true PL2443104T3 (pl) | 2013-08-30 |
Family
ID=42332981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10726756T PL2443104T3 (pl) | 2009-06-19 | 2010-06-15 | Dwupodstawione pochodne ftalazyny będące antagonistami ścieżki hedgehog |
Country Status (35)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA102250C2 (ru) * | 2008-04-29 | 2013-06-25 | Эли Лилли Энд Компани | Двухзамещенные фталазины - антагонисты проводящего пути hedgehog |
| PL2364185T3 (pl) * | 2008-11-03 | 2013-10-31 | Lilly Co Eli | Dipodstawione ftalazyny jako antagoniści szlaku hedgehog |
| US8445493B2 (en) * | 2008-11-17 | 2013-05-21 | Eli Lilly And Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| PT2358698E (pt) | 2008-11-17 | 2012-10-24 | Lilly Co Eli | Antagonistas da via hedgehog de piridazina tetrasubstituída |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| CA2829755A1 (en) | 2011-03-23 | 2012-09-27 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
| WO2015073691A1 (en) | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
| CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
| CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
| BR112017026103B1 (pt) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos |
| AU2016271432A1 (en) | 2015-06-05 | 2017-12-07 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| MY199967A (en) | 2016-03-15 | 2023-11-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
| US10548908B2 (en) * | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
| US11389434B2 (en) | 2017-05-18 | 2022-07-19 | Inserm | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT |
| AU2021360767A1 (en) | 2020-10-13 | 2023-04-27 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (enExample) * | 1977-06-03 | 1981-03-07 | Pfizer | |
| EP0876366B1 (en) | 1996-01-15 | 2001-07-25 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
| JP5067986B2 (ja) | 1998-04-09 | 2012-11-07 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用 |
| GB0013674D0 (en) | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
| ATE443518T1 (de) * | 2001-07-27 | 2009-10-15 | Curis Inc | Vermittler von igel-signalpfaden, zusammensetzungen und relevante verwendungszwecke |
| DE60322869D1 (de) * | 2002-04-22 | 2008-09-25 | Univ Johns Hopkins | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
| WO2004020599A2 (en) | 2002-08-29 | 2004-03-11 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| WO2006004589A2 (en) | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
| US7888364B2 (en) | 2004-09-02 | 2011-02-15 | Curis, Inc. | Pyridyl inhibitors of hedgehog signalling |
| EP1900731A1 (de) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| BRPI0809193A2 (pt) * | 2007-03-15 | 2014-09-23 | Novartis Ag | Compostos orgânicos e seus usos |
| EP2170866B1 (en) * | 2007-06-25 | 2014-08-13 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| CA2697682A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inapropriate hedgehog signalling |
| NZ586121A (en) * | 2007-12-13 | 2012-03-30 | Siena Biotech Spa | Benzimidazole derivatives as hedgehog pathway antagonists and therapeutic applications thereof |
| UA102250C2 (ru) | 2008-04-29 | 2013-06-25 | Эли Лилли Энд Компани | Двухзамещенные фталазины - антагонисты проводящего пути hedgehog |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| ES2433469T3 (es) * | 2008-08-04 | 2013-12-11 | Amgen Inc. | Moduladores de la aurora cinasa y métodos de uso |
| PL2364185T3 (pl) | 2008-11-03 | 2013-10-31 | Lilly Co Eli | Dipodstawione ftalazyny jako antagoniści szlaku hedgehog |
| PT2358698E (pt) | 2008-11-17 | 2012-10-24 | Lilly Co Eli | Antagonistas da via hedgehog de piridazina tetrasubstituída |
| US8445493B2 (en) | 2008-11-17 | 2013-05-21 | Eli Lilly And Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2010
- 2010-06-08 AR ARP100102003A patent/AR077014A1/es active IP Right Grant
- 2010-06-10 JO JO2010188A patent/JO2931B1/en active
- 2010-06-11 TW TW099119158A patent/TWI385165B/zh not_active IP Right Cessation
- 2010-06-15 UA UAA201114996A patent/UA106755C2/uk unknown
- 2010-06-15 EP EP10726756.9A patent/EP2443104B1/en active Active
- 2010-06-15 BR BRPI1011601A patent/BRPI1011601A2/pt not_active Application Discontinuation
- 2010-06-15 MY MYPI2011006137A patent/MY156667A/en unknown
- 2010-06-15 WO PCT/US2010/038568 patent/WO2010147917A1/en not_active Ceased
- 2010-06-15 SI SI201030200T patent/SI2443104T1/sl unknown
- 2010-06-15 NZ NZ596882A patent/NZ596882A/xx not_active IP Right Cessation
- 2010-06-15 CA CA2764542A patent/CA2764542C/en not_active Expired - Fee Related
- 2010-06-15 CN CN201080027189.3A patent/CN102459233B/zh active Active
- 2010-06-15 KR KR1020117030157A patent/KR101389165B1/ko not_active Expired - Fee Related
- 2010-06-15 PE PE2011002119A patent/PE20121050A1/es active IP Right Grant
- 2010-06-15 PT PT107267569T patent/PT2443104E/pt unknown
- 2010-06-15 SG SG2011094190A patent/SG177289A1/en unknown
- 2010-06-15 AU AU2010260244A patent/AU2010260244B2/en not_active Ceased
- 2010-06-15 US US12/815,439 patent/US8273742B2/en active Active
- 2010-06-15 HR HRP20130408AT patent/HRP20130408T1/hr unknown
- 2010-06-15 EA EA201270049A patent/EA019059B1/ru not_active IP Right Cessation
- 2010-06-15 ES ES10726756T patent/ES2409054T3/es active Active
- 2010-06-15 MX MX2011014029A patent/MX2011014029A/es active IP Right Grant
- 2010-06-15 MA MA34455A patent/MA33363B1/fr unknown
- 2010-06-15 DK DK10726756.9T patent/DK2443104T3/da active
- 2010-06-15 JP JP2012516178A patent/JP5596139B2/ja active Active
- 2010-06-15 PL PL10726756T patent/PL2443104T3/pl unknown
-
2011
- 2011-11-22 ZA ZA2011/08587A patent/ZA201108587B/en unknown
- 2011-11-24 IL IL216599A patent/IL216599A/en not_active IP Right Cessation
- 2011-11-29 HN HN2011003139A patent/HN2011003139A/es unknown
- 2011-12-07 TN TNP2011000627A patent/TN2011000627A1/en unknown
- 2011-12-08 CR CR20110658A patent/CR20110658A/es unknown
- 2011-12-13 DO DO2011000386A patent/DOP2011000386A/es unknown
- 2011-12-14 CL CL2011003147A patent/CL2011003147A1/es unknown
- 2011-12-16 EC EC2011011541A patent/ECSP11011541A/es unknown
- 2011-12-22 CO CO11177210A patent/CO6480932A2/es not_active Application Discontinuation
-
2012
- 2012-08-21 US US13/590,481 patent/US9000023B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL216599A0 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| IL208211A0 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| IL211841A0 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| ZA201400310B (en) | Solid dosage form | |
| GB0909680D0 (en) | Dosage form | |
| IL237392B (en) | Pharmaceutical combination | |
| IL220091A0 (en) | Pcsk9 antagonists | |
| GB2473319B (en) | Removable hydraulic-set packer | |
| AP3250A (en) | Tablets for combination therapy | |
| ZA201304617B (en) | Orally disintegrating tablet | |
| EP2389068A4 (en) | HEMGE OF THE HEDGEHOG SIGNAL PATH | |
| ZA201304366B (en) | Orally disintegrating tablet | |
| ZA201200761B (en) | Tablet | |
| AU330360S (en) | Tablet | |
| HUE037291T2 (hu) | Gyógyászati kombináció | |
| GB0920041D0 (en) | Tablet | |
| HU0800414D0 (en) | Pharmaceutical combination | |
| HK1153467A (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| GB0902665D0 (en) | Dosage assembly | |
| AU330359S (en) | Tablet | |
| AU331949S (en) | Tablet | |
| GB0910772D0 (en) | Pharmaceutical | |
| GB0918829D0 (en) | Monitor |